This Plain Language Summary of Publication article (PLSP) from Current Medical Research and Opinion examined whether a booster dose of VLA15, an investigational Lyme disease vaccine, could safely increase antibody levels in adults before tick season. Participants received either 135 or 180 micrograms of VLA15 or placebo at months 0, 2, and 6, with those on the higher dose receiving an additional booster at month 18. This blinded study monitored safety and antibody responses through month 30 to evaluate the vaccine’s effectiveness.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in healthy adults in the USA: results of the booster phase of a randomised, controlled, phase 2 trial’ and was published in the Lancet Infectious Diseases.

Visit The Lancet using the link to read the original article.